diversity

Views & Analysis

The NIH on accelerating research using diverse biomedical da...

Martin Mendoza, PhD, director of health equity and health science policy for the All of Us Research Program at the National Institutes of Health (NIH), tells pharmaphorum about the

Patients

Partner Content

Centring Caregivers

By now, we’re all (hopefully) getting accustomed to the concept of “patient-centricity.” However, another commonly overlooked but equally important group of healthcare stakeholders is careg

Views & Analysis

Rethinking trial engagement and recruitment starts with pati...

With countless media stories regarding COVID-19 published over a period of several years, it was obvious that people around the globe were tuned in to every step of the fight against the pa

R&D

Now is the time for pharma to help solve bias in clinical tr...

Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials.

Patients

Colorful painted group of people figures

To build diversity into clinical trials, collaborate at the ...

Diversity in clinical trials is a “scientific imperative”, but how can industry bridge the gap between “why” and “how”?

News

Study exposes lack of diversity in US cancer trials

Almost half (48%) of cancer clinical trials in the US have no Hispanic or Latin American subjects, and 42% have no black patients, according to a diversity analysis focusing on thousands of